stockportfolio.pro
Cabaletta Bio, Inc. (CABA)
Healthcare · Biotechnology · NasdaqGS
Cabaletta Bio, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | $-12.20M | $-16.94M | $-33.34M | $-46.29M | $-52.98M | $-67.67M | $-115.86M | $-167.86M |
| Net margin | — | — | — | — | — | — | — | — |
Source: Cabaletta Bio, Inc. SEC filings (10-K).
Explore 8 years of Cabaletta Bio, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CABA in your portfolio →
Cabaletta Bio, Inc. financial history by metric
About Cabaletta Bio, Inc.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Cabaletta Bio, Inc. — frequently asked questions
What is Cabaletta Bio, Inc.'s revenue?
Cabaletta Bio, Inc. (CABA) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Cabaletta Bio, Inc. profitable?
No — CABA reported a net loss of $-167.86M in fiscal 2025.
What is CABA's P/E ratio?
Cabaletta Bio, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Cabaletta Bio, Inc. have?
As of fiscal year 2025, CABA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Cabaletta Bio, Inc.'s market cap?
Cabaletta Bio, Inc. (CABA) has a market capitalization of about $500.58M, based on the latest data in our nightly-refreshed cache.
When does Cabaletta Bio, Inc.'s fiscal year end?
CABA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Cabaletta Bio, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.